CD274 and neoplasm: This tumour heterogeneity has recently been shown to impact disease free survival (4) and may also impact the results of Programmed Cell Death Ligand (PD-L1) immunohistochemistry and TMB estimation of samples taken from different parts of a primary tumour, or when assessing regional metastatic lymph nodes.